media – Page 3 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Visara (USA) Acquires Overseas Rights to Haite Bio’s HT006.2.2 Eye Drops

On October 13, 2026, Haitai Bio (300683.SZ) announced that it had signed an exclusive cooperation and licensing agreement with Visara, Inc., a US company, regarding the HT006.2.2 eye drop project. According to the agreement, Visara will obtain exclusive rights outside of Greater China to develop, commercialize, manufacture, contract manufacture, use, sell, offer for sale, import, export, and otherwise utilize the licensor and licensed products of HT006.2.2 eye drops. HT006.2.2 eye drops are a recombinant human nerve growth factor (rhNGF) ophthalmic formulation independently developed by the company with independent intellectual property rights, targeting tropomyosin receptor kinase A (TrkA) and p75 neurotrophic factor receptor (p75NTR). Visara will pay the company an upfront payment of US$7 million plus recent milestone payments. Depending on the progress of clinical development and commercialization, Haitai Bio will also be entitled to receive milestone payments related to research, registration, and commercialization up to a maximum of US$104 million. ...
- Source: drugdu
- 93
- October 16, 2026
Asia Pacific Pharmaceutical’s Shengyao Guangyan Obtains a New Acne Drug Technology Achievement from Quzhou Fudan Research Institute

On October 13, 2026, Zhejiang Shengyao Guangyan Pharmaceutical Co., Ltd. (hereinafter referred to as “Shengyao Guangyan”), a wholly-owned subsidiary of Asia Pacific Pharmaceutical (002370.SZ), signed a “Letter of Intent for Cooperation on Innovative Drug Technology Transaction” with Quzhou Fuda Biomedical Innovation Research Institute (hereinafter referred to as “Quzhou Fudan Research Institute”), intending to introduce all the technological achievements of the Class 1.1 small molecule innovative drug “a BODIPY photosensitizer for acne treatment” held by Quzhou Fudan Research Institute . The target project of this collaboration is a Class 1.1 small molecule innovative drug, “A BODIPY-type photosensitizer for acne treatment,” belonging to the cutting-edge field of photodynamic therapy. It is currently in the PCC (preclinical candidate compound) stage, with one Chinese patent application filed. The indication is acne and other applications. The transaction consideration includes a total of RMB 25 million for R&D and approval milestone payments, a total commercialization milestone ...
- Source: drugdu
- 68
- October 16, 2026
Zelgen Submits a Marketing Application in China for Gecacitinib in Ankylosing Spondylitis

On October 14, 2026, Zekjing Biotechnology (688266.SH) announced that it had submitted a third marketing application for gecacitinib to the National Medical Products Administration for the treatment of active ankylosing spondylitis. Gecacitinib is a novel JAK inhibitor independently developed by the company, which owns the intellectual property rights to the product. Previously, the drug had been approved for marketing by the National Medical Products Administration for two indications: the treatment of intermediate- to high-risk myelofibrosis and severe alopecia areata in adults. The myelofibrosis indication has been included in the 2025 National Reimbursement Drug List. Ankylosing spondylitis is an arthritis characterized by long-term inflammation of the spinal joints, typically manifesting as inflammation of the sacroiliac joints and spinal entheses. The Chinese market for ankylosing spondylitis drugs is projected to reach RMB 17 billion by 2025, with a compound annual growth rate of 12.1% from 2020 to 2025. Source: https://mp.weixin.qq.com/s?__biz=MzA5Njc0MTAxOQ==&mid=2650033491&idx=2&sn=0acfe69713aae899421bc4c8d33101c2&chksm=89939f3bf89bb9f002129378fbe4bfc53f860
- Source: drugdu
- 58
- October 16, 2026
Teva Announces U.S. FDA Approval of WELTRUZA™ (olanzapine) Extended-Release Suspension for Injection

WELTRUZA™ (olanzapine) extended-release suspension for injection is the first and currently the only approved long-acting olanzapine injection (LAI) for the treatment of schizophrenia in adults, administered subcutaneously once a month; treatment requires no loading dose, no oral medication supplementation, and no post-injection monitoring. This approval is based on the results of the pivotal Phase III SOLARIS study. The study showed that WELTRUZA improved overall symptoms, significantly reduced disease severity, and improved individual and social functioning; its systemic safety profile was consistent with that of oral olanzapine.¹ As Teva continues to advance its global “Pivot to Growth” strategy, it will further fulfill its commitment to innovation in the field of patient-centered neuroscience and continue to build a differentiated portfolio of long-acting injectable products. On October 9, Teva Pharmaceutical Industries (NYSE and Tel Aviv Stock Exchange: TEVA) announced that WELTRUZA™ (olanzapine) extended-release suspension for injection has been approved by the U.S. Food ...
- Source: drugdu
- 70
- October 16, 2026
【EXPERT Q&A】If there are no inquiries for a silver member product one month after its launch, what issues should be checked first?

Drugdu.com expert’s response: Suppliers tend to get extremely anxious when their Silver Member products have been online for a month without receiving any inquiries. This reaction is completely understandable. Enterprises sign up for membership, upload products, and wait for overseas buyers to reach out. After a month with no inquiries, it is easy for them to assume the platform is ineffective or their products have no market demand. However, from the perspective of platform operation, the lack of inquiries in the first month should not be judged solely by the result, nor can it be simply concluded that “there are no buyers”. Especially for B2B products such as pharmaceuticals, medical devices, APIs, excipients and consumables, there is an inherent screening process before buyers officially send an inquiry: from searching, browsing, comparing suppliers to making the final decision. Whether the products can be seen, matched by search algorithms, understood and trusted ...
- Source: drugdu
- 71
- October 16, 2026
Oman Health

Organiser：Oman Exhibition Group Time：September 21-23, 2026 Address：P.O. Box 117, P.C. 111, Muscat International Airport, Oman Exhibition hall：Oman International Exhibition Center Product range: Hospital equipment, devices and technologies Surgical instruments, medical-related books, X-ray, CT, MRI, nuclear medical imaging, pharmaceutical and herbal products, home medical equipment, physical therapy, pharmaceutical raw materials, anesthesiology, respiratory equipment, pharmaceutical and packaging equipment, surgical technologies and devices, health care pharmaceuticals, sterilization and disinfection equipment, chemical clinical automatic instruments, first-aid medical equipment and supplies, biotechnology laboratory equipment, surgical instruments and endoscopic equipment, blood bank equipment and refrigeration equipment, general and special diagnostics, dental care and treatment equipment, orthopedic technology and rehabilitation devices, oral care About Oman Health： Oman Health is the largest and most influential medical exhibition in Oman. It showcases products including laboratory equipment, instruments, laboratory supplies, emergency management solutions, medical information and communication technologies, security systems, medical facility design and construction technologies, quality control ...
- Source: drugdu
- 74
- October 15, 2026
【EXPERT Q&A】Why didn’t the buyer contact us again after we got back?

Drugdu.com expert’s response: Many pharmaceutical and medical device enterprises have encountered such a situation when attending exhibitions. They had a great conversation with buyers on site: the buyers listened carefully to the product introduction, asked about specifications, prices, certificates and export experience, and even exchanged business cards or added contact information. At that moment, suppliers would feel that this client is highly promising. However, after the exhibition ends, they have sent the documents and followed up via emails, but the buyers remain unresponsive. This scenario is far from rare, and it cannot be simply interpreted as “the client has no interest” or “the on-site communication was just polite small talk”. In most cases, the on-site conversation at the exhibition is only the first step for buyers to screen suppliers. When attending the exhibition, a buyer may visit dozens of booths in one day, encountering a large number of suppliers offering ...
- Source: drugdu
- 95
- October 14, 2026
Iran PHARMA

Organiser：Iranian Pharmaceutical Industries Syndicate Time：September 24-26, 2026 Address：8FX6+4V9, Mashhad, Razavi Khorasan Province, Iran Exhibition hall：Mashad Fair Ground Product range: Pharmaceutical Machinery：Pharmaceutical preparation production equipment, pharmaceutical water equipment, traditional Chinese medicine processing equipment, refrigeration equipment Packaging Equipment & Materials：Blister packaging machines, filling machines, tablet presses, labeling machines, inkjet printers, anti-counterfeiting printing packaging, packaging production lines, barcode composite technology equipment, self-adhesive printing and packaging equipment, plastic packaging products, packaging container forming, filling and sealing machines, cartoning packaging machines, bag packaging machines, multi-functional bottled packaging machines, glass packaging products, pharmaceutical packaging material production equipment Laboratory Equipment / Analysis & Testing：Laboratory equipment and devices, laboratory consumables, chemical reagents, biochemical/analytical instruments, biotechnology analytical and testing instruments, pharmaceutical testing equipment, food analytical and testing instruments, medical industry analytical instruments Fluid Equipment：Sanitary-grade pumps and valves, fluid engineering pipelines and pipe fittings, microfiltration, ultrafiltration Clean System：Clean air conditioning equipment, clean workstations/benches, clean equipment, anti-static clothing API (Active ...
- Source: drugdu
- 80
- October 13, 2026
【EXPERT Q&A】How to efficiently sort out medical device regulations and corresponding standards?

Drugdu.com expert’s response: When sorting out medical device regulations and standards, the most common mistake is to start reading directly from the regulatory documents themselves. For example, you may immediately dive into MDR, IVDR, FDA Guidance, NMPA announcements, and ISO standard lists. The more materials you read, the more confused you become, and in the end, you cannot figure out exactly what preparation path a specific product should follow. A more efficient approach is to place regulations and standards back into the product scenario first. That is, you need to clarify in advance: which category of product you are sorting out, which market it is intended to enter, what risk class the product belongs to, what documents are required before market launch, and what responsibilities need to be assumed after market launch. Medical device regulations do not exist in isolation, and they must ultimately be applied to a specific product. ...
- Source: drugdu
- 115
- October 12, 2026
CPHI Milan 2026 Recap | What Did Drugdu.com Bring Back from Milan?

From October 6–8, Drugdu.com attended CPHI Milan 2026, meeting with overseas buyers, pharmaceutical companies, and industry partners at Booth 20C65. For Drugdu.com, this was more than simply another overseas exhibition. Every day, product searches, supplier discovery, inquiries, sourcing requests, and overseas promotion all happen online. At the exhibition, those activities became much more tangible. Some visitors were looking for specific products and suppliers. Others wanted to explore new business channels, while some companies sat down with us to discuss overseas markets and promotion plans. After three days in Milan, the most important question for us was not how many people visited the booth. It was: What did we actually bring back from Milan? From Online Data to Real Conversations One interaction at the exhibition stood out to our team. A visitor from Costa Rica came to the Drugdu.com booth and mentioned that he regularly uses Drugdu.com to search for industry ...
- Source: drugdu
- 143
- October 9, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.